↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Seaport Entertainment Group$SEG · filed: grew revenue 18.3% in FY2025 to $130MOld boatNext year $118M–$169M sealedCheck ▾Close ▴
What Seaport Entertainment Group filed
Grew revenue 18.3% in FY2025 to $130 million, operating margin -90.6% against a 7.0% median for miscellaneous amusement & recreation, equity 70.2% of assets. Every figure links to the filing it came from on Seaport Entertainment Group’s card. Old boat: three warning signs.
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $118M and $169M, an 80% range sealed on 27 Sept 2026 · receipt #6562a9 · graded in public by the revenue in Seaport Entertainment Group’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Three biotech IPOs in one week after an eighteen-month freeze; pricing and post-launch performance will determine if capital markets reopen or stall again.
$7.50
per share
$50 million
before underwriter options
$287 million
in total capital raised across four rounds
$195 million
committed since inception
Seaport Therapeutics and Hemab Therapeutics filed S-1 registration statements with the SEC this week while Kailera Therapeutics priced its offering at $7.50 per share, raising $50 million before underwriter options. The trio represents the first cluster of biotech IPO activity since May 2023, when market conditions forced fourteen similar filings into withdrawal or indefinite postponement.
Seaport, a Massachusetts-based neuropsychiatry platform backed by Atlas Venture and Sofinnova, disclosed $287 million in total capital raised across four rounds. The company's lead candidate targets treatment-resistant depression with a novel GABA-A modulator, currently in Phase 2b. Hemab, developing hemophilia gene therapies out of Philadelphia, listed Bain Capital Life Sciences and OrbiMed as anchor investors with $195 million committed since inception. Kailera's pricing came at the low end of its proposed $7.50-$9.50 range, with Leerink Partners and TD Cowen as joint bookrunners. The company plans to allocate proceeds toward advancing its lead oncology program through Phase 1 safety studies by Q3 2025.
The filings arrive as the biotech IPO index climbed 11.3% in Q1 2025, reversing eight consecutive quarters of net outflows. Allocators have been testing receptivity with small tranches—Kailera's $50 million raise is 40% below the $84 million median for comparable-stage oncology IPOs in 2021. The timing suggests underwriters believe a narrow band of institutional buyers will support clinical-stage platforms with defined near-term catalysts, particularly in CNS and rare disease verticals where recent M&A activity has validated asset classes. Seaport's depression program competes in a space where Sage Therapeutics exited with a $435 million acquisition in November, and Hemab's gene therapy approach follows Pfizer's $1.2 billion purchase of a hemophilia B candidate three months prior.
What matters for allocators is whether these three can hold post-IPO valuations long enough to complete their Phase 2 readouts. If Seaport or Hemab file follow-on offerings within twelve months—typical for biotechs burning $60-80 million annually—it signals the window reopened for capital rotation, not fundamental risk appetite. Kailera's pricing at the range floor indicates bookrunners are building in a 15-20% discount for volatility absorption. The real test will be secondary trading volumes in week two and whether retail participation stays below 12% of float, the threshold where momentum-chasing typically destabilizes these names.
Watch for Seaport and Hemab's roadshow schedules, expected within 21 days of effective S-1 dates. If either company prices above midpoint or increases share count, it confirms institutional demand for clinical-stage risk is rebuilding. Track Kailera's stock performance through its first earnings call in late May—any guidance revision on trial timelines will set comps for the next wave of biotech listings already in confidential filing status.
Branded by POPS4 · proof in 60 seconds
For the principal
If you hold pre-IPO biotech stakes, these three names establish the pricing floor for your next liquidity event—watch their first thirty days.
For the operator
Kailera's discount pricing and Seaport's depression focus are direct comps for your neuro portfolio—model secondary dilution risk before adding exposure here.
For the house
We are observing but not allocating; if Seaport holds above issue price through June, we consider small positions in the next CNS filer.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
